Our sectors

To:
postbox@leighday.co.uk
We treat all personal data in accordance with our privacy policy.
Show Site Navigation

From BII to BIA-ALCL – More Transparency is Needed for Women with Breast Implants

Product safety and consumer law solicitor, Sarah Moore, discusses the Victoria Derbyshire show, shown on 22 July 2019, which focussed on the concerning set of symptoms associated with breast implants known as Breast Implant Illness (BII).

Breast implants
Related Areas of Practice:
Sarah Moore specialises in product liability and claims for groups of people who have suffered an injury because of unsafe products. She has written a number of articles on topics such as drug regulation, cigarette packaging and food safety.

BII

The women featured in the BBC piece, both of whom have suffered from BII, emphasized the need for all women to be properly warned about the risks known to be associated with breast implants before undergoing surgery, and called for greater transparency from our regulator, the MHRA, regarding the number of reports of injuries and ‘adverse events’ it has received, in relation to breast implants.
 
At Leigh Day we share those concerns regarding the lack of warnings for women prior to implant surgery, and the lack of transparency regarding the data held by the MHRA concerning breast implants and the complications associated with breast implants.

As highlighted in the Victoria Derbyshire piece, at present, BII is not formally acknowledged as a symptom-set by many clinicians – although the US regulator the FDA and the UK regulator the MHRA, have indicated that they are continuing to investigate BII – and Leigh Day will be monitoring developments regarding BII carefully going forward.

 
BIA-ALCL 

In December 2018, Allergan textured breast implants were removed from the market in Europe due to them being linked to a rare form of cancer called Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL).

Reported symptoms tend to describe a late onset of painful swollen breasts with a fluid collection usually between three and 14 years after implantation. Although investigations into the pathology of BIA-ALCL continue, positive outcomes have been reported and in most cases patients have achieved complete remission.

Leigh Day is currently investigating claims on behalf of women who have had a diagnosis of BIA-ALCL or are being investigated for BIA-ALCL. If you would like to speak to a member of our team regarding a potential BIA-ALCL claim, please email us.

If you have not had a diagnosis of BIA-ALCL but are concerned about developing this condition, and would like to be added to our mailing list so that we can keep you up to date on what we are doing at Leigh Day in regards to BIA-ALCL and inform you if we are able to pursue legal action for you in the future, please complete our questionnaire.

Share this page: Print this page